BD Biosciences
2004
FOUNDED
M&A
STATUS
41-50
EMPLOYEES
M&A
LATEST DEAL TYPE
$205M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of an analytical flow cytometer. The company provides a bench-top cell and bead analysis system for life science researchers; CFlow software for accessing flow cytometry; CSampler, an automated flow cytometry; reagents and kits; and accessories.
Website
Formerly Known As
Accuri Cytometers
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Software
Acquirer
Primary Office
- 173 Parkland Plaza
- Ann Arbor, MI 48103
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore BD Biosciences’s full profile, request a free trial.
BD Biosciences Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 07-Feb-2011 | $205M | 000.00 | 00000 | Completed | Generating Revenue |
| 5. Later Stage VC (Series E) | 12-Jul-2010 | 000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 4. Later Stage VC (Series D) | 13-Jul-2009 | 000 | 000.00 | 000.00 | Completed | Startup |
| 3. Later Stage VC (Series C) | 08-Jul-2008 | 0000 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series B) | 17-Apr-2007 | $5.2M | $5.2M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 01-Feb-2005 | Completed | Startup |
BD Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series D | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 20,958,739 | $0.000010 | $0.02 | $0.25 | $0.25 | 1x | $0.25 | 16.73% |
| Series A | 15,471,493 | $0.000010 | $0.05 | $0.39 | $0.39 | 1x | $0.31 | 15.54% |
BD Biosciences Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000000 | 27-Feb-2017 | 000000000000000000 | Discovery Tools (Healthcare) | ||
| Adaptive Biotechnologies | 06-May-2015 | Later Stage VC | 00000 | Biotechnology |
BD Biosciences Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 000000000 | 06-May-2015 | 00000 00000 00 | 00000 | Completed |
|
BD Biosciences Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000 0000000000 | Discovery Tools (Healthcare) | Los Angeles, CA | 0000 |
BD Biosciences Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Amherst Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Arboretum Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Baird Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Credit Suisse | Investment Bank | Minority | 000 0000 | 000000 0 | ||
| F-Prime Capital Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
BD Biosciences Executive Team (5)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Jeffrey Williams | President & Chief Executive Officer | ||
| Linda McAllister Ph.D | Vice President, Scientific Affairs | ||
| Ger van den Engh Ph.D | Vice President |
2 Former Executives
You’re viewing 3 of 5 executives. Get the full list »